REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer

被引：0
|
作者：
Klajer, E. [1 ]
Jary, M. [1 ,2 ]
Borg, C. [1 ,2 ]
Kim, S. [1 ,2 ,3 ]
Vernerey, D. [2 ,3 ]
Henriques, J. [3 ]
N'Guyen, T. [1 ]
Nasri, M. [1 ]
Almotlak, H. [1 ]
Babre, J. [1 ]
Meurisse, A.
Fratte, S. [4 ]
Fein, F. [5 ]
Calcagno, F. [1 ]
Chanut, L.
Spehner, L. [2 ]
Rebucci-Peixoto, M. [6 ]
Vienot, A. [1 ,2 ]
机构：
[1] Univ Hosp Besancon, Dept Med Oncol, Besancon, France
[2] Univ Bourgogne Franche Comte, Interact Hote Greffon Tumeur Ingn Cellulaire & Ge, INSERM, EFS BFC,UMR1098,RIGHT, Besancon, France
[3] Univ Hosp Besancon, Methodol & Qual Life Oncol Unit, Besancon, France
[4] Nord Franche Comte Hosp, Dept Med Oncol, Besancon, France
[5] Univ Hosp Besancon, Dept Gastroenterol, Besancon, France
[6] Univ Hosp Besancon, Ctr Invest Clin, CIC 1431, Besancon, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
509TiP
引用
收藏
页码：S581 / S581
页数：1
相关论文
共 50 条
  • [21] A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination
    Montagna, E.
    Lai, A.
    Palazzo, A.
    Bagnardi, V.
    Cancello, G.
    Iorfida, M.
    Esposito, A.
    Sangalli, C.
    Munzone, E.
    Goldhirsch, A.
    Colleoni, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S291 - S292
  • [22] PHASE II STUDY OF OXALIPLATIN AS THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Sikder, S. K.
    Rahman, M.
    Saha, R. K.
    ANNALS OF ONCOLOGY, 2010, 21 : 219 - 219
  • [23] Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study
    Tanaka, Maki
    Takamatsu, Yasushi
    Anan, Keisei
    Ohno, Shinji
    Nishimura, Reiki
    Yamamoto, Yutaka
    Masuda, Norikazu
    Mitsuyama, Shoshu
    Tamura, Kazuo
    ANTI-CANCER DRUGS, 2010, 21 (04) : 453 - 458
  • [24] A phase II study of UFT and leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer
    Gyldenkerne, N
    Glimelius, B
    Frödin, JE
    Kjaer, M
    Pfeiffer, P
    Hansen, F
    Keldsen, N
    Sandberg, E
    Jakobsen, A
    ACTA ONCOLOGICA, 2004, 43 (03) : 276 - 279
  • [25] Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study
    Becerra, CR
    Frenkel, EP
    Asrfaq, R
    Gaynor, RB
    INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (06) : 868 - 872
  • [26] Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
    Arora, Sukeshi Patel
    Tenner, Laura
    Sarantopoulos, John
    Morris, Jay
    Liu, Qianqian
    Mendez, Jenny A.
    Curiel, Tyler
    Michalek, Joel
    Mahalingam, Devalingam
    BRITISH JOURNAL OF CANCER, 2022, 127 (06) : 1153 - 1161
  • [27] Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
    Sukeshi Patel Arora
    Laura Tenner
    John Sarantopoulos
    Jay Morris
    Qianqian Liu
    Jenny A. Mendez
    Tyler Curiel
    Joel Michalek
    Devalingam Mahalingam
    British Journal of Cancer, 2022, 127 : 1153 - 1161
  • [28] Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC)
    Bekaii-Saab, Tanios S.
    Ou, Fang-Shu
    Ciombor, Kristen Keon
    Farhat, Mohamed I.
    Kirshner, Jeffrey J.
    Knost, James A.
    Anderson, Daniel M.
    Soori, Gamini S.
    Boland, Patrick Mckay
    Wender, Donald B.
    Desnoyers, Rodwige J.
    Sargent, Daniel J.
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
    Cynthia X. Ma
    Matthew J. C. Ellis
    Gina R. Petroni
    Zhanfang Guo
    Shi-rong Cai
    Christine E. Ryan
    A. Craig Lockhart
    Michael J. Naughton
    Timothy J. Pluard
    Christiana M. Brenin
    Joel Picus
    Allison N. Creekmore
    Tibu Mwandoro
    Erin R. Yarde
    Jerry Reed
    Mark Ebbert
    Philip S. Bernard
    Mark Watson
    Laurence A. Doyle
    Janet Dancey
    Helen Piwnica-Worms
    Paula M. Fracasso
    Breast Cancer Research and Treatment, 2013, 137 : 483 - 492
  • [30] Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)
    Lapeyre-Prost, Alexandra
    Pernot, Simon
    Sigrand, Julie
    Le Malicot, Karine
    Mary, Florence
    Aparicio, Thomas
    Dahan, Laetitia
    Caroli-Bosc, Francois-Xavier
    Lecomte, Thierry
    Doat, Solene
    Marthey, Lysianne
    Desrame, Jerome
    Lepage, Come
    Taieb, Julien
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 285 - 290
12345